Eosinophilic Depletion with Benralizumab, Mepolizumab, and Depemokimab: A Modeling Study
Journal of Asthma and Allergy · 2026-05 · Volume 19 · 1-5
DOI: 10.2147/jaa.s605634 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Asthma and Allergy, 2026-05. Verfasst von Pradeep B Lukka und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, USA. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, USA.
- Pharmetheus, Uppsala, Sweden.
- BioPharmaceutials Medical, AstraZeneca, Gaithersburg, MD, USA.
ORCID-Profile: Pradeep B Lukka, Robert C Penland, Sherri So, David W Boulton
Zitieren
APA
Lukka, P. B., Penland, R. C., Brekkan, A., Ayoun Alsoud, R., So, S., & Boulton, D. W. (2026). Eosinophilic Depletion with Benralizumab, Mepolizumab, and Depemokimab: A Modeling Study. Journal of Asthma and Allergy, Volume 19, 1-5. https://doi.org/10.2147/jaa.s605634
Vancouver
Lukka PB, Penland RC, Brekkan A, Ayoun Alsoud R, So S, Boulton DW. Eosinophilic Depletion with Benralizumab, Mepolizumab, and Depemokimab: A Modeling Study. Journal of Asthma and Allergy. 2026;Volume 19:1-5. doi:10.2147/jaa.s605634
BibTeX
@article{Lukka2026,
author = {Lukka, Pradeep B and Penland, Robert C and Brekkan, Ari and Ayoun Alsoud, Rami and So, Sherri and Boulton, David W},
title = {Eosinophilic Depletion with Benralizumab, Mepolizumab, and Depemokimab: A Modeling Study},
journal = {Journal of Asthma and Allergy},
year = {2026},
volume = {Volume 19},
pages = {1--5},
doi = {10.2147/jaa.s605634}
}
EUVIMED